What acetylcholine does, and why choline sits upstream of it

Acetylcholine was the first neurotransmitter anyone identified, and it is built from a nutrient that has to come in through the diet. This is the path from a meal to a released signalling molecule, and the point on that path where the form of choline stops being interchangeable.

The first neurotransmitter ever identified

In 1921 Otto Loewi stimulated the vagus nerve of an isolated frog heart, collected the fluid around it, and applied that fluid to a second heart. The second heart slowed. Something chemical, not merely electrical, had carried the signal.

He called it Vagusstoff. It was acetylcholine, and it earned Loewi a share of the 1936 Nobel Prize in Physiology or Medicine with Henry Dale.

A century later it remains one of the best-characterised molecules in physiology, which is worth keeping in mind when reading anything that treats it as exotic.

Clean schematic of a synapse, cream ground, forest-green line work, four labelled stages, no glow, no colour gradients, generous white space
Figure 1 Made, released, read, dismantled — in milliseconds Acetylcholine is assembled in the nerve terminal, released into the gap, bound by receptors on the far side, then split apart by an enzyme so the signal ends cleanly. Illustrative schematic of established synaptic physiology.

Where it works in the body

At the junction with muscle

Every voluntary muscle contraction in the body is triggered by acetylcholine crossing the gap between a motor nerve and a muscle fibre. This is not a subtle role.

In the parasympathetic system

It is the main transmitter of the rest-and-digest branch of the autonomic nervous system — slowing the heart, driving digestion and glandular secretion.

In the brain

A set of cholinergic cells in the basal forebrain projects widely across the cortex and into the hippocampus. Those projections are the reason acetylcholine appears in research on attention and on the encoding of new memories.

How a molecule of it gets made

One reaction, two inputs. An enzyme called choline acetyltransferase joins choline to an acetyl group carried by acetyl-CoA, a product of ordinary energy metabolism.

Acetyl-CoA is abundant. Choline has to arrive from somewhere, and that asymmetry is the entire reason choline gets discussed alongside attention at all.

How it gets taken apart

An enzyme, acetylcholinesterase, splits the molecule almost immediately after release. This is a feature: a signal that did not stop would be useless.

Much of the choline released by that split is recaptured by a dedicated transporter on the nerve terminal and used again. The system recycles, which is one reason supply is not a simple story.

Three-panel schematic map, cream ground, forest-green outline shapes, three labelled sites, flat and diagrammatic, no anatomical rendering
Figure 2 One molecule, three jobs Acetylcholine drives skeletal muscle contraction, carries the parasympathetic branch of the autonomic nervous system, and runs the basal forebrain projections into cortex and hippocampus. Illustrative schematic of established physiology.

Where the choline comes from

Mostly from food

The body makes some choline-containing lipid on its own, in the liver, but not enough to cover its requirements. Choline is classed as an essential nutrient, which is the technical way of saying the diet has to supply it.

Mostly as phosphatidylcholine

Very little dietary choline arrives as free choline. Most of it comes bound into phosphatidylcholine, a phospholipid that is a structural component of every cell membrane.

Close crop, four eggs in a chipped ceramic bowl on a worn wooden counter, morning window light from the side, cream background
Figure 3 Choline arrives bound, not free Most choline in food is carried as phosphatidylcholine rather than as the free molecule. Egg yolk and liver are the two foods most associated with it. Illustrative photograph. Per-food amounts are not quoted here; see our citations page.

The pathway that converts one into the other

The route from free choline to membrane phospholipid runs in three steps, and it is worth naming because a popular supplement ingredient is a copy of the intermediate.

  1. Choline is phosphorylated to phosphocholine.
  2. Phosphocholine is combined with a cytidine carrier to make CDP-choline.
  3. CDP-choline is joined to a lipid backbone, producing phosphatidylcholine.

Citicoline, sold as a nootropic, is that second intermediate. Alpha-GPC is what phosphatidylcholine breaks down into. The supplement aisle is largely selling points along one pathway.

Linear three-step pathway diagram, cream ground, forest-green arrows and type, flat, no icons, wide margins
Figure 4 Three steps, and two of them are sold in capsules Choline is converted to phosphocholine, then to CDP-choline, then built into phosphatidylcholine. Citicoline is the middle intermediate; alpha-GPC is a breakdown product of the end point. Illustrative diagram of established biosynthetic chemistry.

Why intake is a live question

Habitual choline intake in the United States remains below the Adequate Intake (Trujillo-Gonzalez et al., American Journal of Clinical Nutrition, 2026; US adults).

In one study of older adults, only 10% of participants met the Adequate Intake for choline (Suzuki et al., Journal of Food Composition and Analysis, 2025; n=203, aged 65 and over).

Neither finding says anything about how any particular person feels. They describe intake distributions in populations, which is all a dietary survey can describe.

Why the form changes what happens next

First, the argument that does not work

It is tempting to assume the researched forms simply carry more choline. They do not, and the arithmetic is easy to check.

Choline itself has a molecular weight of about 104. Choline bitartrate weighs about 253, so choline is roughly 41% of it. Alpha-GPC weighs about 257, so choline is roughly 40% of it. Per milligram, the two deliver almost the same amount of choline.

Anyone arguing for a form on the grounds of choline content is arguing from a number that does not separate them.

Two-bar vertical chart of near-identical height, cream ground, forest-green bars, values labelled above, no gridlines
Figure 5 By weight, the two forms are almost the same Choline accounts for roughly 41% of choline bitartrate and roughly 40% of alpha-GPC by molecular weight. Whatever separates them, it is not how much choline a milligram contains. Molecular-weight arithmetic: choline about 104, choline bitartrate about 253, alpha-GPC about 257.

Second, the argument that does

What separates them is what has been measured. In healthy adults, choline bitartrate has not shown the cognitive benefits people buy it for: one trial gave 1,650 mg a day and found no working-memory performance difference against placebo, though brain activation did change (Dumas et al., 2026; n=20, healthy adults).

That last clause matters. The honest reading is "has not shown the benefit", not "does not reach the brain" — the two are different claims and only one of them is supported.

Third, what is claimed for alpha-GPC, stated at its actual strength

Review-level evidence describes alpha-GPC as able to cross the blood–brain barrier (Putri et al., Neuropsychiatric Disease and Treatment, 2026; narrative review). A narrative review is a summary of other people's work, not a trial, and it is quoted here at that weight and no more.

Research on alpha-GPC in healthy adults has run at roughly 250–630 mg a day. Higher figures appear in marketing, but those trials were run in people with diagnosed cognitive impairment — a different population, and not transferable. Both sides of that are in how much alpha-GPC the research actually used, and the form comparison is in alpha-GPC vs choline bitartrate.

Two-bar vertical chart with overlapping error bars, near-identical heights, cream ground, forest-green bars, no gridlines
Figure 6 A negative result, drawn A trial of 1,650 mg a day of choline bitartrate in healthy adults found no working-memory performance difference against placebo, while brain activation did differ. Dumas et al., 2026 · n=20 · healthy adults · 1,650 mg a day.

The three forms side by side

Form Where it sits on the pathway Choline by weight What has been measured in healthy adults
Choline bitartrate Free choline, paired with tartaric acid About 41% No working-memory performance difference against placebo at 1,650 mg a day (Dumas et al., 2026; n=20)
Citicoline (CDP-choline) The middle intermediate Lower per milligram — the molecule carries a cytidine group as well Researched separately; frequently branded
Alpha-GPC A breakdown product of phosphatidylcholine About 40% Trials have run at roughly 250–630 mg a day

Four things this does not mean

Acetylcholine is not a fuel, and choline is not a fuel. Supply and demand at a nerve terminal are not the same as a tank being filled.

More is not linearly better. Choline has an upper intake level, and very high intakes are associated with a fishy body odour caused by a bacterial breakdown product.

Gut bacteria also convert some choline into a compound that has been studied in relation to cardiovascular risk. That work is unsettled, and it is a reason for care rather than alarm.

And attention is not one molecule. Dopamine, noradrenaline and several other systems are involved, and any account that names a single chemical is a simplification for the sake of a sentence.

Close crop, two white capsules resting in an open palm, morning window light, matte cream background
Figure 7 What a capsule can and cannot settle A supplement supplies a compound in a stated amount. Whether that changes anything measurable is a separate question, answered by trials rather than by mechanism. Illustrative photograph.

Mechanism is not evidence

Every step above is well established, and none of it proves that swallowing choline does anything in particular.

A plausible pathway explains why a trial might be worth running. It does not stand in for the trial, and a great deal of supplement copy relies on the reader not noticing the substitution.

What all of this reduces to, on a label

One word, inside the parentheses: alpha-GPC, citicoline or choline bitartrate. Three separately researched compounds on one shelf at similar prices, distinguished by a term almost nobody reads.

Finding it takes about ten seconds, using the sequence in how to read a Supplement Facts panel in about sixty seconds.

Macro crop, a single panel row showing an ingredient name and its bracketed form, matte paper, soft raking light, cream ground
Figure 8 The whole distinction, in one bracket The chemical form is declared within the ingredient's parenthetical. It is the shortest piece of text on the pack that changes what was bought. Formatted per 21 CFR 101.36. Illustrative crop.

Where we stand

Weal Focus uses alpha-GPC at 300 mg, printed on the panel with the form named. That is a statement about which compound is in the capsule and what quantity of it, and it is checkable against any other pack on the same shelf.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Sources for every figure, with the population studied in each, are on our citations page.